New device performs better than old for removing blood clots
American Stroke Association Late-Breaking Science - Abstract 4436-LB 8 - Embargoed until 8 am CT/ 9 am ET
- In a small study comparing two devices, an experimental mechanical blood clot remover called the SOLITAIRE; Flow Restoration Device outperformed an FDA-approved mechanical clot remover, known as the MERCI; retriever.
- More patients treated with the new device had successfully reopened blood vessels without an increase in symptomatic bleeding in the brain.
- Patients treated with the new device were more likely to survive and less likely to have mental or motor impairment three months after a stroke.
NEW ORLEANS, Feb. 3, 2012 - An experimental blood clot-removing device outperformed the FDA-approved MERCI; retriever device, according to late-breaking science presented at the American Stroke Association’s 2012 International Stroke Conference.
The SOLITAIRE; Flow Restoration Device is a self-expanding stent-based design that mechanically removes blood clots from blocked vessels after a stroke. After insertion into the clot using a thin tube, or catheter, the device traps the clot then both device and clot are removed, restoring blood flow. The MERCI retriever uses a tiny corkscrew, guided by a balloon-tipped wire, to snare and remove the blood clot.
In the Solitaire With the Intention for Thrombectomy (SWIFT) trial, the first U.S. clinical trial to compare the two devices, 113 stroke patients at 18 hospitals were randomly assigned to undergo clot removal with either device within eight hours of stroke onset between Feb. 2010-Feb. 2011.
The trial was ended at the suggestion of a safety monitoring committee nearly a year earlier than planned due to significantly better outcomes with the new device. The experimental device opened blocked vessels without causing symptomatic intracranial hemorrhage in 61 percent of patients. The currently approved device had the same result in 24 percent of cases - a statistically significant difference, said Jeffrey L. Saver, M.D., lead author of the study, professor of neurology and director of the Stroke Center in the Geffen School of Medicine at the University of California in Los Angeles.
The use of the new device also led to better survival three months after stroke. There was a 17.2 percent mortality rate with the new device versus 38.2 percent with the older one.
Stroke caused by a blood clot blocking a blood vessel supplying the brain is the most common type of stroke, accounting for about 87 percent of all strokes. The FDA-approved treatment for stroke with the most robust body of evidence is use of a clot-busting drug, but the drug must be given within 4.5 hours of symptom onset, and more quickly in older patients. When clot-busting drugs cannot be used or are ineffective, the clot can sometimes be mechanically removed, during or even after the 4.5 hours. The study didn’t compare mechanical clot removal to drug treatment.
Although not yet approved in the United States, the new device is approved in Europe.
Other specific findings - all of which were statistically significant - were:
- Two percent of SOLITAIRE-treated patients had symptoms of bleeding in the brain compared to 11 percent of MERCI patients.
- At the 90-day follow-up, overall adverse event rates, including bleeding in the brain, were similar for the two devices.
- Fifty-eight percent of SOLITAIRE-treated patients had good mental/motor functioning at 90 days compared to 33 percent of MERCI patients.
- The SOLITAIRE device also opened more vessels when used as the first treatment approach, necessitating fewer subsequent attempts with other devices or drugs.
Patients’ average age was 67 years and 68 percent were male. Forty percent had not improved with standard clot-busting medication prior to the study, while the remainder had not received it.
The time from the start of symptoms to start of the clot retriever treatment was on average 4.9 hours for SOLITAIRE and 5.3 hours for MERCI. The study results account for this time difference.
“This heralds a new era in acute stroke care,” said Saver. “We’re going from our first generation of recanalization procedures, which were only moderately good in reopening target arteries, to now having a highly effective recanalization device. This really is a game-changing result.”
Co-authors are: Reza Jahan, M.D.; Elad Levy, M.D.; Tudor G. Jovin, M.D.; Blaise Baxter, M.D.; Raul Nogueira, M.D.; Wayne Clark, M.D.; Ronald Budzik, M.D.; Osama O. Zaidat, M.D, and the SWIFT Trial Investigators. Author disclosures are on the abstract.
Covidien, the SOLITAIRE manufacturer, funded the study.
Statements and conclusions of study authors that are presented at American Heart Association scientific meetings are solely those of the study authors and do not necessarily reflect association policy or position. The association makes no representation or warranty as to their accuracy or reliability. The association receives funding primarily from individuals; foundations and corporations (including pharmaceutical, device manufacturers and other companies) also make donations and fund specific association programs and events. The association has strict policies to prevent these relationships from influencing science content. Revenues from pharmaceutical and device corporations are available at www.heart.org/corporatefunding.
NR12-1022 (ISC 2012/Saver)
(Note: Actual presentation is 12 p.m. CT, Friday, Feb. 3, 2012.)
- Any downloadable video/audio interviews, B-roll, animation and images related to this news release are located on the right column of the release link located at newsroom.heart.org/pr/aha/_prv-new-device-performs-better-than-228372.aspx
- General ISC video and ISC photos available at newsroom.heart.org/ISC12-Video or newsroom.heart.org/ISC12-Photos.
- Follow news from ASA International Stroke Conference 2012 via Twitter: twitter.com/#!/heartnews. Follow #ASANews12.
ASA News Media Office in Dallas: (214) 706-1396
ASA News Media Office in New Orleans, Feb. 1-3: (504) 670-6010
For Public Inquiries: (800) AHA-USA1 (242-8721)